US House passes track and trace bill after reconciling differences with Senate

By Zachary Brennan contact

- Last updated on GMT

Related tags: Drug supply chain, Authentication, Drugs

New legislation will put a system in place to track the US drug supply chain
New legislation will put a system in place to track the US drug supply chain
The US House on Saturday passed legislation that calls for the tracking and tracing of pharmaceuticals through the nation's supply chain after agreeing on the bill with the Senate last week.

Under the Drug Quality and Security Act​, manufacturers by 2015 will have to create electronic tracking systems to find and root out suspect or counterfeit drugs. The tracking system will enable companies to investigate supply chain partners more closely, and will be required to keep records of investigations into suspect products for at least six years following the investigations.

House Energy and Commerce Committee Chairman Fred Upton (R-Mich.) said, “This legislation would also create a uniform national standard for drug supply chain security to protect Americans against counterfeit drugs while eliminating needless government red tape​.”

Support from the bill is coming from industry, as well, which will be hit with the cost of putting such a standard in place​.

In a letter of support for the bill, Pfizer added, “This bill will increase the security of the United States’ already strong drug supply chain by creating a national traceability system and replacing the patchwork of state laws now in place. Specifically, this bill provides greater safeguards for patients by requiring the placement of unique serial numbers on each drug package, and tracking them as they move through the distribution system, lessening the threat of illicit and counterfeit medicines entering the drug supply chain​.”

A number of other associations offered letters of support for the bill, which will bypass committee hearings and move straight to the Senate floor this week.

Details of the Bill

Beginning four years after the Drug Supply Chain Security Act is enacted, manufacturers will have to provide electronic transactions information and histories. In addition, they will have to affix a product identifier to each package and keep the identifier on the package for a minimum of six years after the date of the transaction.

The transaction information will have to include:

—   The proprietary or established name or names of the product;

—   The strength and dosage form of the product;  

—   The National Drug Code number of the product;

—   The container size;

—   The number of containers;

—   The lot number of the product;

—   The date of the transaction and the date of the shipment; and

—   The business name and address of the person from whom ownership is being transferred and the business name and address of the person to whom ownership is being transferred.

The legislation introduced last week would also preempt state laws such as California’s e-pedigree law​, which is calling on companies to implement the tracking tags between 2015 and 2017.

The draft will also replace existing draft legislation under consideration in the Senate and a bill that already passed the House in June.

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more